Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10276985 | 0.91 | TACR3 (1.00) | TACR3 | |
| SCHEMBL12500585 | 0.91 | TACR3 (1.00) | TACR3 | |
| SCHEMBL10277473 | 0.89 | TACR3 (1.00) | TACR3 | |
| SCHEMBL10277231 | 0.87 | TACR3 (1.00) | TACR3 | |
| SCHEMBL10277656 | 0.86 | TACR3 (1.00) | TACR3 | |
| SCHEMBL10277025 | 0.85 | TACR3 (1.00) | TACR3 | |
| SCHEMBL10277600 | 0.85 | TACR3 (1.00) | TACR3 | |
| SCHEMBL16239673 | 0.84 | TACR3 (0.73) | TACR3 | |
| SCHEMBL10277140 | 0.83 | TACR3 (1.00) | TACR3 | |
| SCHEMBL10277211 | 0.83 | TACR3 (1.00) | TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661432-B1 | PYRROLIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | claimed |
| US-8618303-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-12-31 | — | — | US | claimed |
| US-20120178761-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-12 | — | — | US | claimed |
| EP-2661432-B1 | PYRROLIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| EP-2661432-B1 | PYRROLIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-8618303-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120178761-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-20120178761-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-20120178761-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-12 | — | — | US | disclosed |
| WO-2012093109-A1 | PYRROLIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178761-A1 | PYRROLIDINE DERIVATIVES | SLC6A3, NPSR1, TACR1 | TACR3 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.